


et syndromes malformatifs











Cohorte ELENA

Pr David GENEVIEVE 15 Septembre 2017

WORKSHOP elena



Unité Inserm U1183 Département de Génétique médicale Hôpital Arnaud de Villeneuve, CHRU Montpellier






- Does ASD is an environmental disorder?
- Does ASD is a genetic disorder ?


Does ASD is a feature of several genetic disorders?

- Why having an answer?
 - What is the goal?




Why an exact aetiology?


 A precise diagnostic to propose a precise counselling and a precise care (treatment?)



- What lead to the increase of the incidence of ASD?
 - Environment ? Toxics?




- What lead to the increase of the incidence of ASD ?
 - Environment ? Toxics?



Rates of autism correlate *perfectly*
with sales of organic foods

- What lead to the increase of the incidence of ASD?
 - Environment ? Toxics?



Rates of autism correlate *perfectly*
with sales of organic foods


As well as the number of Jim Carrey movies

How to reach the precise aetiology?



Genetic could help in ASD?


Heritability in ASD around 80%



DISEASE MECHANISMS

Genetic architectures of psychiatric disorders: the emerging picture and its implications

Patrick F. Sullivan¹, Mark J. Daly² and Michael O'Donovan³



VOLUME 13 | AUGUST 2012 | 537


Concepts in genetics

- Heredity (different from heritability)
 - Several mode of inheritance are observed
 - No familial history doesn't means no Mendelian disorders

TRANSLATIONAL GENETICS


Rare-disease genetics in the era of next-generation sequencing: discovery to translation

Kym M. Boycott, Megan R. Vanstone, Dennis E. Bulman and Alex E. MacKenzie



Increased maternal and paternal age?








Insee Institut national de la statistique et des études économiques Mesurer pour comprendre

âge de la mère





Increased maternal and paternal age?

Rate of *de novo* mutations and the importance of father's age to disease risk

Augustine Kong¹, Michael L. Frigge¹, Gisli Masson¹, Soren Besenbacher^{1,2}, Patrick Sulem¹, Gisli Magnusson¹, Sigurjon A. Gudjonsson¹, Asgeir Sigurdsson¹, Aslaug Jonasdottir¹, Adalbjorg Jonasdottir¹, Wendy S. W. Wong³, Gunnar Sigurdsson¹, G. Bragi Walters¹, Stacy Steinberg¹, Hannes Helgason¹, Gudmar Thorleifsson¹, Daniel F. Gudbjartsson¹, Agnar Helgason^{1,4}, Olafur Th. Magnusson¹, Unnur Thorsteinsdottir^{1,5} & Kari Stefansson^{1,5}

23 AUGUST 2012 | VOL 488 | NATURE | 471





Decoding germline de novo point mutations

Does *de novo* mutation due to increase paternal age is responsible for the increasing of the prevalence of ASD?

Exome sequencing in sporadic autism spectrum disorders identifies severe *de novo* mutations

Brian J O'Roak¹, Pelagia Deriziotis², Choli Lee¹, Laura Vives¹, Jerrod J Schwartz¹, Santhosh Girirajan¹, Emre Karakoc¹, Alexandra P MacKenzie¹, Sarah B Ng¹, Carl Baker¹, Mark J Rieder¹, Deborah A Nickerson¹, Raphael Bernier³, Simon E Fisher^{2,4}, Jay Shendure¹ & Evan E Eichler^{1,5}



Frequency and Complexity of De Novo Structural Mutation in Autism

The American Journal of Human Genetics 98, 1–13, April 7, 2016

William M. Brandler, ^{1,2,3,12} Danny Antaki, ^{1,2,3,4,12} Madhusudan Gujral, ^{1,2,3,12} Amina Noor, ^{1,2,3} Gabriel Rosanio, ^{1,2,3} Timothy R. Chapman, ^{1,2,3} Daniel J. Barrera, ^{1,2,3} Guan Ning Lin, ² Dheeraj Malhotra, ^{1,2,3} Amanda C. Watts, ⁴ Lawrence C. Wong, ⁵ Jasper A. Estabillo, ⁵ Therese E. Gadomski, ^{1,2,3} Oanh Hong, ^{1,2,3} Karin V. Fuentes Fajardo, ^{1,2,3} Abhishek Bhandari, ^{1,2,3} Renius Owen, ⁶ Michael Baughn, ⁴ Jeffrey Yuan, ⁴ Terry Solomon, ⁴ Alexandra G. Moyzis, ⁴ Michelle S. Maile, ^{1,2,3} Stephan J. Sanders, ⁷ Gail E. Reiner, ⁸ Keith K. Vaux, ⁸ Charles M. Strom, ⁶ Kang Zhang, ⁹ Alysson R. Muotri, ³ Natacha Akshoomoff, ⁵ Suzanne M. Leal, ¹⁰ Karen Pierce, ¹¹ Eric Courchesne, ¹¹ Lilia M. Iakoucheva, ² Christina Corsello, ⁵ and Jonathan Sebat^{1,2,3,*}

71 patients ASD, non affected siblings, parents)


De novo mutations are frequent in ASD

- De novo mutations seems frequent in ASD (and ID)
- Could Explain
 - absence of familial history
 - Increased incidence of ASD

TRANSLATIONAL GENETICS


Rare-disease genetics in the era of next-generation sequencing: discovery to translation

Kym M. Boycott, Megan R. Vanstone, Dennis E. Bulman and Alex E. MacKenzie




Does ASD is a disease or feature of genetic disorders?

- ASD observed in an isolated or in a syndromic form
 - ID is a comorbidity?



Stratification into ASD patients +/- ID


Co-existence of ID and ASD



Stratification into ASD patients

Co-existence of ID and ASD 2012





Focus on genetic of ID



Does Mendelian disorders are frequent in ID?




Genetic studies in intellectual disability and related disorders

Lisenka E. L. M. Vissers¹, Christian Gilissen¹ and Joris A. Veltman^{1,2}

NATURE REVIEWS | GENETICS

VOLUME 17 | JANUARY 2016 |



Does Mendelian disorders are frequent in ID?




Genetic studies in intellectual disability and related disorders

Lisenka E. L. M. Vissers¹, Christian Gilissen¹ and Joris A. Veltman^{1,2}

NATURE REVIEWS | GENETICS

VOLUME 17 | JANUARY 2016 |



A link between the genetic of ID and ASD?

APPLICATIONS OF NEXT-GENERATION SEQUENCING

Genetic studies in intellectual disability and related disorders

Lisenka E. L. M. Vissers¹, Christian Gilissen¹ and Joris A. Veltman^{1,2}

NATURE REVIEWS | GENETICS | VOLUME 17 | JANUARY 2016 |



Does ASD as well as ID are features of genetic disorders?


APPLICATIONS OF NEXT-GENERATION SEQUENCING

Genetic studies in intellectual disability and related disorders

Lisenka E. L. M. Vissers¹, Christian Gilissen¹ and Joris A. Veltman^{1,2}


NATURE REVIEWS | GENETICS

VOLUME 17 | JANUARY 2016 |



Concept of features Vs co-morbidities

ID is a comorbidity or a feature?



Concept of features Vs co-morbidities

• Penetrance of features, including ASD, in X fragile syndrome

Co-Occurring Conditions Associated With *FMR1* Gene Variations:

Findings From a National Parent Survey

Donald B. Bailey Jr,* Melissa Raspa, Murrey Olmsted, and David B. Holiday American Journal of Medical Genetics Part A 146A:2060–2069 (2008)

TABLE III. Frequency of Reported Developmental Delay and Other Conditions for Premutation Males Compared With a Sample of Normal Males Matched on Age and Family Income

Condition	Premutation males $(n = 57)$	Non-FX males (n = 57)	
Developmental delay	33.0***	1.8	
Attention problems	41.1*	21.4	
Hyperactivity	28.1	14.0	
Aggressiveness	19.3*	5.3	
Self-injury	8.9	1.8	
Autism	19.3*	5.3	
Seizures	11.3**	1.2	
Anxiety	33.3**	8.8	
Depression	10.7	10.7	

Developmental Delay (DD) or Intellectual Disability (ID): 96%

Attention Problems: 84%

Anxiety: 70%

Hyperactivity: 66%

Autism: 46%

Self-Injury: 41%

Aggressiveness: 38%

Obesity: 30% (near general population in USA)

Seizures: 18% Depression: 12%


^{*}P < 0.05

^{**}P < 0.01

^{***}P < 0.001


Penetrance of features in a precise diangosis = genetic disorder

- Penetrance of ASD in fragile-X syndrome
- Variability of the expression of features in a genetic disorder







Expanding features in Fragile X syndromes Deciphering the genetic aetiologies = knowledge for patients



Expanding features in Fragile X syndromes Deciphering the genetic aetiologies = knowledge for patients



Expanding features in Fragile X syndromes Deciphering the genetic aetiologies = knowledge for patients



Does ASD is a feature of genetic disorders? Examples


O APPLICATIONS OF NEXT-GENERATION SEQUENCING

Genetic studies in intellectual disability and related disorders

Lisenka E. L. M. Vissers¹, Christian Gilissen¹ and Joris A. Veltman^{1,2}

NATURE REVIEWS | GENETICS

VOLUME 17 | JANUARY 2016 |



• *POGZ – De Novo* mutation

	FR2
Mutation	c.2400dup (p.Lys801 Glnfs*7)
Age (years)	11
Gender	F
ID/DD	+
Speech or language delay	+
Motor delay	+
ASD	_
Microcephaly	i —
Feeding problems	-
Vision problems	_
Obesity tendency	+

Disruption of *POGZ* Is Associated with Intellectual Disability and Autism Spectrum Disorders

Holly A.F. Stessman, 1,28 Marjolein H. Willemsen, 2,3,28,* Michaela Fenckova, 2,3 Osnat Penn, 1 Alexander Hoischen, 2,3 Bo Xiong, 1 Tianyun Wang, 4 Kendra Hoekzema, 1 Laura Vives, 1 Ida Vogel, 5 Han G. Brunner, 2,3,6 Ineke van der Burgt, 2 Charlotte W. Ockeloen, 2 Janneke H. Schuurs-Hoeijmakers, 2 Jolien S. Klein Wassink-Ruiter, 7 Connie Stumpel, 6 Servi J.C. Stevens, 6 Hans S. Vles, 8 Carlo M. Marcelis, 2 Hans van Bokhoven, 2,3 Vincent Cantagrel, 9,10 Laurence Colleaux, 9,10 Michael Nicouleau, 9,10 Stanislas Lyonnet, 9,10,11 Raphael A. Bernier, 12 Jennifer Gerdts, 12 Bradley P. Coe, 1 Corrado Romano, 13 Antonino Alberti, 13 Lucia Grillo, 14 Carmela Scuderi, 15 Magnus Nordenskjöld, 16 Malin Kvarnung, 16 Hui Guo, 4 Kun Xia, 4 Amélie Piton, 17,18 Bénédicte Gerard, 18 David Genevieve, 19 Bruno Delobel, 20 Daphne Lehalle, 21 Laurence Perrin, 22 Fabienne Prieur, 23 Julien Thevenon, 21 Jozef Gecz, 24 Marie Shaw, 24 Rolph Pfundt, 2 Boris Keren, 25,26 Aurelia Jacquette, 25 Annette Schenck, 2,3 Evan E. Eichler, 1,27,29, * and Tjitske Kleefstra 2,3,29

The American Journal of Human Genetics 98, 541–552, March 3, 2016

• POGZ _____

Mutation	
	Asn882Lysfs*14 de novo
Age (years)	13
Gender	F
ID/DD	+
Speech or language delay	+
Motor delay	+
ASD	+
Microcephaly	-
Feeding problems	-
Vision problems	+
Obesity tendency	-

• *CNOT3*

De novo NM_014516.3:c.439G>A, p.(Glu147Lys)

Severe ID

Walk 30 months

no language

Seizures

ASD

Short stature

Relative macrocephaly

• *CNOT3*

• De novo NM_014516.3:c.1537_1540delAGTG, p.(Ser513Metfs*27)

Learning difficulties ASD

No Seizures Normal growth parameters

Mendelian is not All







Environment and ASD

Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism

Jakob Christensen, PhD, Therese Koops Grønborg, MSc, Merete Juul Sørensen, PhD, Diana Schendel, PhD, Erik Thorlund Parner, PhD, Lars Henning Pedersen, PhD, and Mogens Vestergaard, PhD

JAMA. 2013 April 24; 309(16): 1696-1703.


	No.		Adjusted Hozard		
	Unexposed	Exposed	Adjusted Hazard Ratio (95% CI)	!	
Valproate	·	·	, ,		
Total	655 107	388			
Childhood autism	2058	7	4.9 (2.3-10.3)		-
Autism spectrum disorder	5423	12	3.0 (1.7-5.4)		
Oxcarbazepine					
Total	655 205	321			
Childhood autism	2064	1	1.0 (0.1-6.9)		
Autism spectrum disorder	5427	7	2.1 (0.96-4.6)		
Lamotrigine					
Total	654747	647			
Childhood autism	2062	4	1.7 (0.5-5.2)		
Autism spectrum disorder	5426	8	1.7 (0.8-3.5)		
Clonazepam					
Total	655 233	269			
Childhood autism	2063	2	0.9 (0.1-6.7)		
Autism spectrum disorder	5431	3	0.7 (0.2-2.9)		
Carbamazepine					
Total	655 153	386			
Childhood autism	2065	2	1.4 (0.4-5.8)		
Autism spectrum disorder	5433	4	1.0 (0.4-2.8)		
					П
				0.1 1.0	10
				Adjusted Hazard Ratio (95% CI)	

ASD and valproic acid



In France 2007-2015

15 000 pregnancy with in utero exposition to valproic acid 1,9/1000 pregnancy



2017



Ne pas utiliser chez les filles, adolescentes, femmes en âge de procréer ou enceintes, sauf en cas d'échec des autres traitements

[*] Le nom de la spécialité concernée (Dépakine, Micropakine, Dépamide, Dépakote, génériques) sera indiqué à cet endroit.

Conclusions (for now)

- We need to decipher using exome or genome the ASD "feature" in an attempt to
 - Have a precision diagnostic = genotype = Mendelian disorder
 - Propose a genetic counselling
 - Recurrence or not
 - Adapt the cure and the prevention of the features (phenotype) based on
 - the knowledge of the genetic disease,
 - the penetrance of the associated features
 - and the age of apparition of these features
 - Avoid exposition to known exogenous factors (valproic acid for instance)



Deciphering ASD on other features

IMMEDIATE COMMUNICATION

Targeted sequencing and functional analysis reveal brain-size-related genes and their networks in autism spectrum disorders

Molecular

Molecular Psychiatry (2017) 22, 1282-1290

Jinchen Li^{1,8}, Lin Wang^{1,8}, Hui Guo¹, Leisheng Shi², Kun Zhang², Meina Tang¹, Shanshan Hu², Shanshan Dong¹, Yanling Liu¹, Tianyun Wang¹, Ping Yu², Xin He³, Zhengmao Hu¹, Jinping Zhao⁴, Chunyu Liu^{1,5}, Zhong Sheng Sun^{2,6} and Kun Xia^{1,7}

536 patients with ASD > 294 genes tested (genes supposed to be involved in brain size) > 22 patients with mutations

Deciphering ASD on other features

IMMEDIATE COMMUNICATION

Targeted sequencing and functional analysis reveal brain-size-related genes and their networks in autism spectrum disorders

Jinchen Li^{1,8}, Lin Wang^{1,8}, Hui Guo¹, Leisheng Shi², Kun Zhang², Meina Tang¹, Shanshan Hu², Shanshan Dong¹, Yanling Liu¹, Tianyun Wang¹, Ping Yu², Xin He³, Zhengmao Hu¹, Jinping Zhao⁴, Chunyu Liu^{1,5}, Zhong Sheng Sun^{2,6} and Kun Xia^{1,7}

Molecular Psychiatry (2017) 22, 1282-1290


536 patients with ASD > 294 genes tested (genes supposed to be involved in brain size) > 22 patients with mutations = 4%

Chr.	Position	Ref	Alt	Gene symbol	GenBank No.	Effect	Nucleotide change	AA. alteration	DNMs in SSC or ASC	PH (percentile)	RVIS (percentile
DNMs	21062265		_	CHD8	NIM 001170620	F	- FC00 dum A	- D1007f-	71-50	0.637 (10.30()	2 227 (1 20/)
chr14	21862265 ^a	-	Т	CHD8	NM_001170629	Framesnirt	c.5688aupA	p.R1897fs	7 LoF, 2 Dmis	0.637 (10.3%)	- 2.337 (1.2%)
chr14	21862296	AG	_			Frameshift	c.5657delAG	p.T1886fs			
chr21	38853069 ^a	G	T	DYRK1A	NM 001396	Stop-gain	c.457G>T	p.E153X	4 LoF	0.658 (9.6%)	-0.422 (25.6%
chrX	153296471 ^b	G	A	MECP2	NM 001110792	Stop-gain	c.844C>T	p.R282X	1 Dmis	0.359 (24.3%)	-0.885 (10.5%
chr11	64457918	-	G	NRXN2	NM_015080	Frameshift	c.808dupG	p.A270fs	-	0.197 (43.7%)	-2.164 (1.4%)
chr1	151402109 ^a	G	A	POGZ	NM_207171	Stop-gain	c.379C>T	p.Q127X	3 LoF	0.192 (44.5%)	- 1.527 (3.4%)
chr2	166179813 ^a	C	Т	SCN2A	NM_001040143		c.1819C>T	p.R607X	4 LoF, 7 Dmis	0.566 (12.7%)	- 1.990 (1.8%)
chr2	166170189a	C	T			Missense	c.1094C>T	p.T365M			
chr9	3248164	TA	_	RFX3	NM 001282116	Frameshift	c.1835delTA	p.L612fs	_	0.934 (2.5%)	-0.799 (12.5%
chr4	114275103 ^b	G	C	ANK2	NM_001148	Missense	c.5329G>C	p.V1777L	4 LoF, 4 Dmis	0.953 (2.0%)	-3.329 (0.4%)
chr8	1877564	G	A	ARHGEF10	NM_014629	Missense	c.3034G>A	p.A1012T	1 Dmis	0.192 (44.6%)	- 1.016 (8.1%)
chr9	136913560	C	T	BRD3	NM_007371	Missense	c.731G>A	p.R244Q	-	0.437 (18.8%)	-0.705 (14.8%
chr15	49048380	T	C	CEP152	NM_001194998	Missense	c.3065 A > G	p.Q1022R	_	0.139 (57.8%)	0.972 (90.2%
chr1	240072174	A	T	CHRM3	NM_000740	Missense	c.1423 A>T	p.1475F	1 Dmis	0.177 (47.5%)	-0.136 (43.8%
chr1	53676893	T	C	CPT2	NM_000098	Missense	c.1547 T > C	p.F516S	_	0.115 (66.5%)	0.514 (80.3%
chr5	127702120	T	G	FBN2	NM_001999	Missense	c.2252 A > C	p.E751A	-	0.625 (10.7%)	- 1.868 (2.0%)
chr12	52635307	A	G	KRT7	NM_005556	Missense	c.745 A > G	p.M249V	-	0.250 (35.4%)	1.067 (91.7%
chr18	48241495	G	A	MAPK4	NM_001292040	Missense	c.593G > A	p.R198Q	_	0.136 (58.7%)	-0.511 (21.7%
chr16	14340619	C	T	MKL2	NM_014048	Missense	c.1502C>T	p.S501F	-	0.316 (27.9%)	- 1.549 (3.3%)
chr22	36697021	C	T	MYH9	NM_002473	Missense	c.2714G>A	p.R905H	1 Dmis	0.259 (34.3%)	- 1.994 (1.7%)
chr9	134396829	C	T	POMT1	NM_001136114	Missense	c.1444C>T	p.R482W	-	0.134 (59.6%)	-0.301 (32.3%
chr9	71849443	T	C	TJP2	NM_001170415	Missense	c.1772 T > C	p.L591S	-	0.302 (29.1%)	1.459 (95.2%
Hemizyg	ous variations										
chrX		C	T	ATRX	NM_138270	Missense	c.6280G > A	p.V2094I	_	NA	-0.926 (9.8%)
chrX	18622983	C	A	CDKL5	NM_003159	Missense	c.1939C>A	p.P647T	-	0.432 (19.1%)	-0.667 (15.9%
chrX	153594754	C	T	FLNA	NM_001110556	Missense	c.1150G>A	p.V384M	-	0.752 (7.1%)	-3.240 (0.4%)
chrX	13771497	G	C	OFD1	NM_003611	Missense	c.1066G>C	p.E356Q	1 LoF, 1 Dmis	0.106 (70.4%)	-0.176 (40.6%
chrX	153694155	A	T	PLXNA3	NM_017514	Stop-gain	c.2497 A>T	p.K833X	1 LoF	0.114 (66.9%)	-2.494 (0.9%)
chrX	153698849	C	T			Missense	c.5051C>T	p.S1684L			
chrX	154493543	G	A	RAB39B	NM_171998	Missense	c.31C>T	p.L11F	-	0.432 (19.1%)	0.013 (54.69
chrX	152959387	C	A	SLC6A8	NM 001142805		c.C1139A	p.P380Q	1 LoF	0.415 (20.2%)	-0.737 (13.9%

Epigenetics or mutations in genes controlling epigenetics?

LaSalle JM. Autism genes keep turning up chromatin. OA Autism 2013 Jun 19;1(2):14.

Gene name	Aliases	Human chromo- some location	Human disease	Protein function Binds mCpG, repression, chromatin dynamics		
MECP2	Methyl CpG- binding protein 2, ARBP	Xq28	Rett syndrome, autism (rare mutation or aber- rant methylation)			
ATRX	RAD54, XH2	Xq21.1	Thalassaemia, intellec- tual disabilities	SWI/SNF chromatin remodel- ling, ATPase/helicase domain		
H2AFY	MAC- ROH2A1.1	5q31.1	Autism (association)	Histone H2 variant, X chromo- some inactivation		
SMC1A	Cohesin, CDL52	Xp11.22	Cornelia de Lange syn- drome	Chromosome cohesion		
MAC- ROD2		20p12.1	Autism (association)	O-acetyl-ADP-ribose deacety- lase, binds this metabolite from histone deacetylation		
KDM5C	JARID1C, SMCX	Xp11.22	ASD, ID (rare mutations)	Histone demethylase of H3K4, gene repression		
MBD1	сххсз	18q21	Autism (rare mutations), also rare variants in related genes MBD4, MBD5	Binds mCpG, links mCpG to H3K9me3		
ARID1B	BAF250B	6p25.3	Coffin-Siris syndrome, mental retardation auto- somal dominant type 12 (MRD12), autism (rare)	Component of SWI/SNF chro- matin remodelling complex, AT-rich binding domain		
SMAR- CC1	BAF155	3p31.21	Autism (rare mutation)	Component of SWI/SNF chro- matin remodelling complex and neuronal BAF complex (nBAF)		
SMAR- CC2	BAF170	12q13.2	Autism (rare mutation)	Component of SWI/SNF chro- matin remodelling complex and nBAF		
JMJD1C	TRIP8	10q21.3	Autism (rare mutation, translocation, abnormal methylation)	Histone demethylase for H3K9, hormone-dependent transcrip- tional activation		
CHD8	AUTS18	14q11.2	Autism (rare mutation), also rare autism vari- ants in family members CHD1, CHD3, CHD7)	ATP-dependent chromatin helicase, negative regulator of Wnt signalling pathway by regu- lating beta-catenin (CTNNB1)		



Constant progression of Knowledge

Review

Intellectual disability and autism spectrum disorders: Causal genes and molecular mechanisms

Anand K. Srivastava, Charles E. Schwartz*

Neuroscience and Biobehavioral Reviews 46 (2014) 161-174




Fig. 1. Etiological causes of intellectual disability. Percentages are based on the evaluation of 15,484 individuals seen by the Greenwood Genetic Center.




APPLICATIONS OF NEXT-GENERATION SEQUENCING

Genetic studies in intellectual disability and related disorders

Lisenka E. L. M. Vissers¹, Christian Gilissen¹ and Joris A. Veltman^{1,2}

NATURE REVIEWS | GENETICS

VOLUME 17 | JANUARY 2016 |




Concepts in genetics

Effect of genetic variants

Rare variant with strong effect vs frequent variant without or only weak effect

Mendelian disorders Penetrant variant

- Mutation
- CNV
 - 22q13 (SHANK3)
 - 22q11,2



Frequent variant Weak effect


SNP from GWAS

CNV in ASD (and ID)

Convergence of Genes and Cellular Pathways Dysregulated in Autism Spectrum Disorders

2446 patients

The American Journal of Human Genetics 94, 1-18, May 1, 2014



22g11 duplication syndrome (n=5, 2 dn, 3 inh)

Xq28 duplication including GDI1 (n=2, 1 dn, 1 XL mat)

Rare, large, de novo CNV (n=3, 1.6-4.5 Mb)

CNV disrupting ASD and/or ID genes

NRXN1 exonic deletion (n=8, 4 dn, 4 inh)
NRXN1 intragenic duplication (n=1, dn)

HDAC4 exonic deletion (n=1, inh)

SYNGAP1 exonic deletion (n=1, dn)

ARID1B exonic deletion (n=1, dn)

SHANK2 exonic deletion (n=3, 3 dn)

CHD2 exonic deletion (n=1, dn)

SHANK3 exonic deletion (n=1, dn)

PTCHD1 exonic deletion (n=1, XL mat)

IL1RAPL1 intragenic duplication (n=1, XL mat)

DMD exonic deletion (n=2, XL mat)

DMD exonic duplication (n=1, XL mat)

CASK partial duplication (n=1, XL mat)


Genomic disorders, nonrecurrent breakpoints


Terminal 9p deletion (n=1, dn)


Kleefstra syndrome (9q34.3 deletion) (n=1, dn)


Jacobsen syndrome (11q deletion) (n=1, dn)


Phelan-McDermid syndrome (22q13 deletion) (n=3, 3 dn)













8000 genetic diseases


Increased maternal and paternal age and incidence of ASD?



Estimated autism prevalence in the world



Complexe diseases



The same gene is responsible for several disorders

One gene, many neuropsychiatric disorders: lessons from Mendelian diseases

Xiaolin Zhu1, Anna C Need1,2, Slavé Petrovski1,3 & David B Goldstein1

NATURE NEUROSCIENCE VOLUME 17 | NUMBER 6 | JUNE 2014

